BioSpace News Archive

Neurent Medical Receives FDA Clearance for NEUROMARK ™, A Novel Multi-Point Nerve Disruption Treatment for Chronic Rhinitis.

Apollo Therapeutics today announced the appointment of Dr. Sanjay Aggarwal as the company’s chief medical officer.

NorthStar Medical Radioisotopes, LLC (‘NorthStar’), and IBA (Ion Beam Applications S.A., EURONEXT), today announced a new contract in which NorthStar will purchase a third Rhodotron® TT300 HE electron beam accelerator from IBA.

Aerami Therapeutics, Inc. (the “Company”), a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Barry Deutsch as chief financial officer effective November 15, 2021.

Beroni Group, an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, announced that it has received part payment of a US$1.07M order for its SARS-CoV-2 Antigen Test Kit from a Japanese pharmaceutical company based in Tokyo.

Betagenon AB, today announced the publication by co-founder Prof. Helena Edlund of a new study demonstrating that in aged mice the pan-AMPK activator O304 improves cardiac function and exercise capacity, while preventing and reversing age-associated hyperinsulinemia and insulin resistance.

Exact Sciences Corp. (NASDAQ: EXAS) today announced an agreement with Jefferson Health (Jefferson) to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test.

Simulations Plus, Inc. today announced that it presented simulation results performed with the quantitative systems pharmacology model, NAFLDsym, to help explain the relatively high positive response rates in placebo cohorts.

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, provided an update on clinical development plans for Brilacidin, the Company’s defensin-mimetic drug candidate being evaluated in clinical testing for multiple indications.

ImStem Biotechnology, Inc., a biopharmaceutical company pioneering the development of human embryonic stem cell derived mesenchymal stem cells through a proprietary method using a trophoblast intermediate stage, announced the dosing of the first US multiple sclerosis patient with its lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.